Central nervous system and peripheral inflammatory processes in Alzheimer's disease: Biomarker profiling approach

Frontiers in Neurology

Volumn 6, Issue Aug, 2015, Pages

  Delaby, Constance ^a   Gabelle, Audrey ^a,b   Blum, David ^c   Schraen Maschke, Susanna ^c   Moulinier, Amandine ^a   Boulanghien, Justine ^a   Séverac, Dany ^d   Buée, Luc ^c   Rème, Thierry ^a   Lehmann, Sylvain ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

Alzheimer disease; Biomarkers; Cerebrospinal fluid; Inflammation; Serum

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL3 CHEMOKINE; FATTY ACID BINDING PROTEIN 3; GRO ALPHA; IGFBP6 PROTEIN; INTERLEUKIN 3; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TAU PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER THE CURVE; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYDROCEPHALUS; IMMUNOPATHOGENESIS; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84940983111     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00181     Document Type: Article

References (34)

1. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's disease: a source of heterogeneity and target for personalized therapy. Neuroscience (2014) 302:103-11. doi:10.1016/j.neuroscience.2014.09.061
2. Akiyama H. Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21(3):383-421. doi:10.1016/S0197-4580(00)00124-X
3. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol (2015) 14(4):388-405. doi:10.1016/S1474-4422(15)70016-5
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6(3):131-44. doi:10.1038/nrneurol.2010.4
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 82(12):4245-9. doi:10.1073/pnas.82.12.4245
6. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 83(13):4913-7. doi:10.1073/pnas.83.13.4913
7. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 69(10):1318-25. doi:10.1001/archneurol.2012.1282
8. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 13(11):1359-62. doi:10.1038/nm1653
9. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One (2011) 6(12):e28092. doi:10.1371/journal.pone.0028092
10. Llano DA, Laforet G, Devanarayan V. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 25(1):73-84. doi:10.1097/WAD.0b013e3181f5b8d8
11. Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement (2014) 10(6):799e-807e. doi:10.1016/j.jalz.2014.05.1749
12. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 79(9):897-905. doi:10.1212/WNL.0b013e318266fa70
13. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 4(1):65-79. doi:10.2217/bmm.09.84
14. Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. Alzheimers Res Ther (2013) 5(2):10. doi:10.1186/alzrt164
15. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 6(4):419-30. doi:10.2217/bmm.12.46
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 34(7):939-44. doi:10.1212/WNL.34.7.939
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 56(3):303-8. doi:10.1001/archneur.56.3.303
18. Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther (2014) 6(3):38. doi:10.1186/alzrt267
19. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One (2012) 7(4):e34341. doi:10.1371/journal.pone.0034341
20. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia (2001) 35(1):72-9. doi:10.1002/glia.1072
21. Laske C, Stransky E, Hoffmann N, Maetzler W, Straten G, Eschweiler GW, et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res (2010) 7(5):409-14. doi:10.2174/156720510791383813
22. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 74(9):1200-5. doi:10.1136/jnnp.74.9.1200
23. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 178(5):829-41. doi:10.1083/jcb.200705042
24. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 173(6):1768-82. doi:10.2353/ajpath.2008.080528
25. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiol Exp (Wars) (2008) 68(4):526-34.
26. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta-and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor-and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem (2000) 275(11):7918-24.
27. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?. Neurotherapeutics (2007) 4(4):590-601. doi:10.1016/j.nurt.2007.07.004
28. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol (1998) 153(1):31-7. doi:10.1016/S0002-9440(10)65542-3
29. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol (2002) 127(1-2):160-8. doi:10.1016/S0165-5728(02)00112-1
30. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev (2014) 42:93-115. doi:10.1016/j.neubiorev.2014.02.001
31. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 6(4):e18850. doi:10.1371/journal.pone.0018850
32. Hanzel CE, Iulita MF, Eyjolfsdottir H, Hjorth E, Schultzberg M, Eriksdotter M, et al. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis (2014) 40(3):667-78. doi:10.3233/JAD-132282
33. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology (2008) 71(14):1057-64. doi:10.1212/01.wnl.0000306313.89165.ef
34. Cheon MSet al. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl (2003) 67:225-34.